Interleukin-12 electroporation may sensitize ‘cold’ melanomas to immunotherapies
Bottom Line: Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association…